Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug
More than three years after raising a $45 million B round to get its lead drug into the clinic for wet age-related macular degeneration, two of PanOptica’s investors have come back with an $11 million add-on to do some more Phase I/II work with what they’re calling a next-gen formulation.
Third Rock and SV Health Investors are providing the Series B(b) funds to get a topical drug back into the clinic. In the first try at the Bernardsville, NJ-based biotech, researchers say they got a positive biological response in about half of the patients. But there clearly must have been some shortcomings with corneal toxicity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.